Affiliation:
1. Department of Neurology, Mainz Comprehensive Epilepsy and Sleep Medicine Center Johannes Gutenberg‐University Mainz Germany
2. Department of Neurology Philipps‐University Marburg Marburg Germany
3. Rudolf Frey Educational Clinic Johannes Gutenberg‐University Mainz Germany
4. Department of Neurology, Focus Program Translational Neuroscience (FTN), Rhine Main Neuroscience Network University Medical Center of the Johannes Gutenberg University Mainz Mainz Germany
Abstract
AbstractObjectiveDue to the high mortality of patients with refractory status epilepticus (SE), new antiseizure medications (ASMs) are needed to improve long‐term outcomes. In this study, we evaluated the efficacy and safety of eslicarbazepine acetate (ESL), a new sodium channel blocker, based on the data from a large epilepsy register.MethodsData on the efficacy and safety of ESL for the treatment of refractory SE were gathered from the Mainz Epilepsy Registry (MAINZ‐EPIREG). Logistic regression was applied to identify predictors of status interruption.ResultsIn total, 64 patients with remote symptomatic refractory SE were treated with ESL. No cases of idiopathic generalized epilepsy were included. The average age was 61.4 ± 11.0 years. The median number of administered ASMs before the start of ESL was three. On average, 2 days had elapsed since the onset of SE before the administration of ESL. The initial dose of 800 mg/day was increased up to a maximum daily dose of 1600 mg in case of nonresponse. In 29 of 64 patients (45.3%), the SE could be interrupted within 48 h of ESL therapy. In patients with poststroke epilepsy, the control of SE was achieved in 62% of patients (15/23). The earlier initiation of ESL therapy was an independent predictor of control of SE. Hyponatraemia occurred in five patients (7.8%). Other side effects were not observed.SignificanceBased on these data, ESL may be used as an adjunct therapy for the treatment of refractory SE. The best response was found in patients with poststroke epilepsy. In addition, early initiation of ESL therapy appears to result in better control of SE. Besides a few cases of hyponatraemia, no other adverse events were detected.
Subject
Neurology (clinical),Neurology,General Medicine
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献